Lantheus and GE Healthcare Propose Global Deal for CAD Imaging Agent

GE Healthcare and Lantheus Medical Imaging signed a term sheet for the continued Phase III development and global commercialization of Lantheus’s flurpiridaz F 18, a positron emission tomography (PET) myocardial perfusion imaging (MPI) agent for diagnosing coronary artery disease.The proposed deal, which the firms announced late yesterday, would see GE Healthcare take over all funding for the program, including a second Phase III study, and global commercialization. Priority territories in